Understanding the Health Economics of Alzheimer’s Disease and Dementias
April 25, 2025 - 07:17
A special themed section of research papers has been published, shedding light on the intricate health economics surrounding Alzheimer's disease and related dementias (ADRD). This collection aims to provide essential insights as the aging population continues to expand and new treatments are developed. The research highlights the multifaceted economic challenges posed by ADRD, including the financial burden on healthcare systems and the impact on patients and caregivers.
As the prevalence of dementia rises, understanding the economic implications becomes increasingly critical for policymakers and healthcare providers. The findings emphasize the need for a comprehensive approach to address the long-term care costs, the value of innovative therapies, and the importance of investing in preventive measures. This body of work not only serves as a valuable resource for future research but also aims to guide effective policy decisions in managing ADRD, ultimately improving outcomes for patients and society as a whole.
MORE NEWS
May 20, 2026 - 08:17
Why renaming this common hormonal disorder is a huge dealYou probably know someone who has a condition that, until last week, was known as PCOS, or polycystic ovary syndrome. It affects one in eight women of reproductive age. But despite being so common,...
May 19, 2026 - 21:27
ABC7's Tracy Butler provides health updateLongtime ABC7 meteorologist Tracy Butler offered a candid health update to her audience, revealing details about a recent medical challenge. During a live segment, Butler explained that she had...
May 19, 2026 - 04:46
Why the WakeMed - Atrium Health hospital merger mattersHospital executives worked in secret for two years to finalize the merger between WakeMed Health and Hospitals and Atrium Health, a deal that will fundamentally alter the healthcare landscape in...
May 18, 2026 - 09:33
World Economic Forum: women’s health gets only 20% of R&D funding. We must seize this $1 trillion opportunityA fresh analysis backed by the Gates Foundation and Wellcome Leap has spotlighted a glaring imbalance in medical research. According to the data, less than 3% of all clinical trials are designed...